In November 2016, proinnovera was awarded with the acquisition and conduct of a phase III rescue study in bacterial infected eczema by a mid-sized German pharmaceutical company focused on the development of medicinal products for dermatology. Upon takeover, proinnovera significantly increased the recruitment rate which was well below plan at that time. 104% of the projected patients were randomized four months faster than planned and the recruitment rate increased fourfold.
Facts and Results
|Enrollment Period||10 months, aiming for September 2017 for LPFV according to the current enrollment speed at takeover||Enrollment closed 4 months ahead only after 6 months in May 2017|
|Enrollment Rate||11,5 patients per month according to enrollment rate at takeover||43 patients per month|
|Number of sites||11||15 including 4 proinnovera sites|
The key to the successful takeover and the earlier closure of enrollment is proinnovera’s well-established site network and the strategic selection of eligible sites based on the following criteria: